iOS 18.6.1 And watchOS 11.6.1 Launch With Restored Blood Oxygen Feature In The U.S.
By the end of 2023, this legal battle briefly forced Apple to halt Apple Watch Series 9 and Apple Watch Ultra 2 sales. Then, by the beginning of 2024, the company resumed sales of the smartwatches, but without the blood oxygen functionality. More frustrating for users, if they needed to repair an Apple Watch, it would lose support for this previously built-in functionality.
In a press release shared earlier this morning, the company announced that these users will now have access to "redesigned blood oxygen features by updating their paired iPhone to iOS 18.6.1 and their Apple Watch to watchOS 11.6.1." According to the company, the captured data will be measured and calculated on the iPhone, with the results available in the Respiratory section of the Health app.
Read more: How To Control An iPad With Your iPhone
Blood Oxygen's Comeback Is Good News For Future Apple Watch Features
While Apple says nothing is changing for those who purchased a newer Apple Watch outside the U.S., it's good to see this functionality making a comeback in one of Apple's most important markets.
More than that, restoring blood oxygen support could also lead to other new health features. In a previous report, Bloomberg suggested that Apple plans to add blood pressure monitoring to the Apple Watch Series 11. The device is expected to be unveiled next month alongside the iPhone 17.
The blood pressure technology is expected to follow the same path as the blood oxygen and sleep apnea functionalities, where Apple warns users that there might be something wrong depending on the measurements. While the sensors won't have the same FDA approval certificate as the ECG sensor, at least it's going to be something users can check with the watch.
Read the original article on BGR.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Opendoor stock pops 10% as company says CEO will step down
Opendoor Technologies (OPEN) shares spiked as 8% in early trading Friday after the company announced that CEO Carrie Wheeler will step down, effective immediately. The company's board appointed Opendoor's chief technology and product officer Shrisha Radhakrishna as president and interim leader of the company. Opendoor, which uses iBuyer real estate technology to flip homes, said it was searching for a new CEO. Since going public through a SPAC transaction in 2020, Opendoor has yet to post a profitable quarter. The company received a warning in May that it faced potential delisting from the Nasdaq after trading under $1 for more than 30 days. Shares have surged more than 200% in the past month, powered in part by Carvana (CVNA) turnaround spotter EMJ Capital and speculative investors on Reddit's wallstreetbets, a haven for meme stocks. EMJ Capital founder and president Eric Jackson said in an X post on July 14 that his firm was taking a long position in Opendoor, which was then trading under $1 per share. "The communication on the earnings call from the CEO and the CFO was really awful," Jackson told Yahoo Finance last week. Jackson has been critical of Opendoor's top leadership, most recently following the company's latest quarterly results in early August, when the stock sank 20% following disappointing earnings forecast. Year-to-date Opendoor shares are up 100%. Sign in to access your portfolio
Yahoo
13 minutes ago
- Yahoo
Electrophysiology Market worth US$21.72 billion by 2030 with 11.6% CAGR
DELRAY BEACH, Fla., Aug. 15, 2025 /PRNewswire/ -- The global Electrophysiology Market, valued at US$11.41 billion in 2024, stood at US$12.55 billion in 2025 and is projected to advance at a resilient CAGR of 11.6% from 2025 to 2030, culminating in a forecasted valuation of US$21.72 billion by the end of the period. The rise of the electrophysiology market can be attributed to several drivers: the increasing prevalence of cardiovascular diseases, including arrhythmias and atrial fibrillation; patients and healthcare providers are increasingly favoring minimally invasive procedures over traditional surgical interventions; electrophysiological techniques, such as catheter ablation, offer less invasive options for treating certain cardiac arrhythmias; and government support and initiatives aimed at improving healthcare infrastructure and funding research and development in electrophysiology also contribute to market growth. Download PDF Brochure: Browse in-depth TOC on "Electrophysiology Market" 322 - Tables62 - Figures330 - Pages By product, in 2024, electrophysiology ablation catheters are expected to be the leading segment in the medical device market. This anticipated growth is largely driven by the rising global prevalence of atrial fibrillation (AF) and various cardiac arrhythmias, which has increased the demand for minimally invasive ablation techniques. Recent technological advancements in catheter design, such as the introduction of contact force-sensing mechanisms, irrigated-tip designs, and high-power short-duration (HPSD) ablation systems, have greatly enhanced procedural safety, precision, and clinical outcomes. These innovations are contributing to wider acceptance and increased utilization of these catheters within the medical community. By indication, the electrophysiology market, divided by medical indications, includes segments such as atrial fibrillation, atrial flutter, and atrioventricular nodal reentry tachycardia. Atrial flutter, characterized by rapid heartbeats from the atria, is increasingly common, especially among the elderly, due to age-related cardiac changes. This rising prevalence has created a demand for advanced diagnosis and treatment options tailored to atrial flutter. Innovations in catheter ablation, advanced imaging techniques, and new pharmacological therapies reflect the urgency for effective arrhythmia management in an aging population. By geography, in 2024, North America, primarily the US and Canada, is set for significant growth in the medical technology market. The region is a global leader in medical innovations, especially in electrophysiology, often adopting breakthroughs ahead of others. With some of the highest healthcare spending globally, the US influences the uptake of advanced medical technologies, enhancing patient outcomes and operational efficiency. Strong A investment in research and development fosters innovation and creates a robust marketplace for new products and services, solidifying North America's role as a key driver of growth in the medical technology sector. Request Sample Pages : As of 2024, prominent players in the electrophysiology market are Johnson & Johnson Services, Inc. (US), Abbott (US), Medtronic (Ireland), Koninklijke Philips N.V. (Netherlands), GE Healthcare (US), Boston Scientific Corporation (US), Japan Lifeline Co., Ltd (Japan), Stereotaxis, Inc. (US), MicroPort Scientific Corporation (China), and BIOTRONIK (Germany). Abbott (US): Abbott Laboratories is a comprehensive healthcare company that operates across diverse sectors, including pharmaceuticals, medical devices, diagnostics, and nutrition. The company has established a significant presence in electrophysiology, particularly in the development of advanced medical devices for cardiac electrophysiology procedures. Abbott's portfolio in this specialized market includes sophisticated mapping systems, electrophysiology catheters, and related technologies designed for the precise diagnosis and management of cardiac arrhythmias. Furthermore, Abbott is likely engaged in ongoing research and development initiatives aimed at innovating and enhancing electrophysiological technologies to improve patient outcomes and procedural efficiencies. Koninklijke Philips N.V. (Netherlands) Koninklijke Philips N.V. Philips, a Netherlands-based multinational company, is a significant player in the healthcare sector, particularly within medical technology. The company develops an extensive range of products that enhance capabilities in cardiology, patient monitoring, diagnostic imaging, and electrophysiology. In the electrophysiology domain, Philips offers advanced solutions aimed at the identification and management of cardiac arrhythmias. This product suite includes high-precision imaging technologies, advanced mapping systems, and specialized electrophysiology catheters, all essential tools utilized by cardiology professionals. Key offerings include the EP WorkMate system, which serves as a comprehensive electrophysiology recording and reporting platform, facilitating efficient data capture and analysis during procedures. Additionally, Philips has introduced state-of-the-art X-ray imaging systems designed for enhanced visualization during electrophysiological interventions. The EP Navigator and EP-XT Mapping system are also part of their innovative portfolio, providing clinicians with advanced three-dimensional mapping capabilities that improve procedural accuracy and patient outcomes. For more information, Inquire Now! Related Reports: Defibrillator Market Cardiac Monitoring & Cardiac Rhythm Management Devices Market Ablation Technology Market Catheters Market Digital X-ray Market Get access to the latest updates on Electrophysiology Companies and Electrophysiology Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets
Yahoo
13 minutes ago
- Yahoo
Why Trump might push for a US gov't. stake in Intel
Intel (INTC) stock is popping following reports that the US government is considering taking a stake in the legacy chipmaker after Trump's meeting with Intel CEO Lip-Bu Tan. Slatestone Wealth chief market strategist and host of Yahoo Finance's Trader Talk, Kenny Polcari, and Yahoo Finance Senior Reporter Allie Canal join Opening Bid to take a closer look at what the reported government partnership could mean for the US, Intel, and the evolving chip landscape. To watch more expert insights and analysis on the latest market action, check out more Opening Bid. All right, let's fire up, uh, my stock of the day. The Trump administration is reportedly in talks with Intel to have the US government take a stake. Uh, Intel declined to comment specifically on this to me, but they did say this, uh, quote, Intel's deeply committed to supporting President Trump's efforts to strengthen US technology and manufacturing leadership. Uh, the questions here are many though. One, why would the administration even want to stake in an Intel that is scary behind chief rivals Nvidia and AMD? President Trump has interacted a lot with Nvidia CEO Jensen Huang and has got a taste as to what it means to be a leader in semiconductors. Two, why would Intel want to get in bed with the government at a time in which CEO Lipu Tang and the board must act quickly to reorganize the company. I find it hard to believe the government will be a quiet minority shareholder. There's a lot of stake here, as Intel is and should be a beacon of US chip making, not the punching bag it has become. The company's financials have taken a major hit with sales down for more than three straight years and earnings evaporating in the process. A lot going on there. Still with me, my round table, Kenny, Paul Kerry, uh, Slate Stone Wealth chief market strategist, David Seif, Nomora chief economist, and Yahoo Finance reporter, senior reporter, Allie Canal. Kenny, I want to go over to you. Um, any interest in going long in Intel on news like this, uh, even in the, uh, keeping the back of your mind, or maybe just putting the front of your mind that this is a fundamentally, uh, just wrong company. I mean, nothing's going right for them. Uh, uh, agree. So Intel's not a name that I've ever owned, uh, and we don't own it here. But look, I it's certainly has a pop because of the news. But is the pop temporary? I'm not even sure. And I agree with you. Why would you want to get, why would the government want to now be partners with Intel? Why would Intel want to be partners with the government? And what does that say about future opportunities? Is the government now going to start this Trump going to start the stick his hand in other companies? Kenny, it's like the auto bailout. I mean, it reminds me of when they took a stake in GM, what, 15, 20 years ago. 100%. And so I'm a little bit I'm a little bit confused about that. But Intel's not a name that I ever owned at all. I think there's other places to put your money in the space. But so this news does nothing in terms of getting me excited about, oh, I got to jump on this Intel bandwagon. I do not. David, does the, does it benefit, um, the US economy to have a healthy Intel? Or at this point, the semiconductor industry led by Nvidia, AMD, and of course, Taiwan semiconductor, they have just passed this company by, and our economy can go chugging along relying on chips from these three companies. Yeah, I mean, you know, I don't have much to say about individual companies, but certainly, um, you know, the US has a multi-century track record of doing well by sort of not sticking its nose into things and allowing, allowing the private market to go where it may. Um, to the extent that Intel has been lagging behind, uh, it it may be the best thing for the economy to simply allow it to, uh, continue to either wither or sink or swim, so to speak, um, and allow the current leaders to continue to lead and only lose their lead if they actually get out competed. Uh, Allie, uh, we're just about almost two weeks away from that Nvidia earnings report. And it will look starkly different to what Intel put up a few weeks ago. And it's night and day. I mean, these are, these companies both might be making computer chips, but they couldn't be more different. Couldn't be more different. And Intel, I just feel like it's too late for the company to really catch up to AMD, to Nvidia. Of course, for the Trump administration, they're viewing this as an issue of national security, that they really want to make sure that Intel can survive through this volatile time. We did have the that CEO meeting with President Trump, and really we've seen that across the board of big tech, right? Apple CEO, Tim Cook, met with Trump recently. And then out of that meeting was a $100 billion investment in the US. So that is President Trump's goal. He wants to bring manufacturing production, all the things, including all the chip makers back onto the domestic soil. But they also have other types of agreements that they're rolling out that are very unique and really unprecedented. One of those being that revenue share agreement with Nvidia and AMD. They're letting them sell some of their chips to China for a kickback, for some of the revenue to the federal government. So there's just a lot of moving parts and moving pieces to this. It's still an unconfirmed report. Intel did say that they are looking forward to working with the government, but they didn't confirm whether or not this was actually happening. So it feels like the US is just going to continue to be involved in some of these companies, at least throughout the term of Trump's presidency. What ultimately comes from that and the legacy that leads and how it really changes what we view the the chip supply chain as at this current moment, that remains to be seen. Related Videos How Trump's meeting with Putin impacts investors Buffett's Berkshire Hathaway sold Apple shares. Should you? Intel Soars as Trump Considers US Stake in Chipmaker 3 AI chip stocks that are best positioned right now Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
